Financial terms of the deal were not disclosed.
This is the first collaboration utilizing Novimmune’s new kappa-lambda bispecific antibody technology. The proprietary platform generates fully human antibodies which target two specific binding sites with one antibody.
Novimmune CEO Jack Barbut said: "The kappa-lambda platform is exactly the right technology for therapy areas which need a bispecific antibody that is as close to a natural human antibody as you can get.
Bispecific antibodies currently used in biopharmaceutical applications have been constructed using chemical linkers, non-human material, antibody fragments or forced engineering, he said.
Head of Research Nicolas Fischer said: "Our kappa-lambda antibodies are allowed to assemble naturally.
"So, they have promising development and safety characteristics such as a longer half-life, increased stability and a lower risk of provoking an unwanted reaction in patients."